Somnus submits 510(k) for Somnoplasty RF ablation system for habitual snoring.
This article was originally published in The Gray Sheet
SOMNUS 510(k) FOR SOMNOPLASTY ABLATION SYSTEM TO TREAT HABITUAL SNORING was submitted to FDA the week of April 14, the company says. The submission includes data from a 40-patient study conducted at the Stanford University Medical Center that evaluates use of Somnus Medical Technologies' Somnoplasty system for reducing snoring.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.